Metabolism slows, muscle mass declines, hormonal shifts alter how the body stores fat, and the caloric deficit required to produce meaningful weight loss becomes more difficult to sustain through diet and exercise alone
In January 2025, the FDA approved an oral form of Novo Nordisks Wegovy (semaglutide) to treat obesity
A small subset of patients (approximately 10 to 15% based on clinical patterns) achieve moderate weight loss (10 to 15% of body weight), maintain that loss for 12+ months at a stable dose, build strong dietary and exercise habits, and express confidence in maintaining without medication
L-GLUTAMINE 2000 for Immune Support: Extend your focus beyond appearance and muscle mass with L-GLUTAMINE 2000, delivering a full 2 grams of L-glutamine per serving
Your dose is too low for your body weight This is not strictly a compounding issue, but it is far more common with compounded semaglutide because many online telehealth clinics prescribe conservatively